Thursday, March 05, 2015 9:56:14 PM
Gilman formerly of Cubist
http://www.lifescienceleader.com/doc/cubist-the-curtain-closes-0001
Just jumped ship to a new ABX play
http://www.twst.com/update/99526-scynexis-inc-scynexis-inc-appoints-steven-c-gilman-phd-to-board-of-directors
I sure don't miss the bureaucracy that goes along with a 2,000 person company. 20 employees is better.
I posted this WSJ Pharmalot piece a while back but maybe you didn't see. Merck granting incredibly favorable terms to NGM ... If only CTIX could strike such a sweetheart deal. Liked the little guys redefinition of the Golden Rule.
MERCK/NGM
http://www.wsj.com/articles/BL-270B-1540
I think what makes this deal somewhat unusual is that we are able to retain the autonomy to pursue various discovery stage programs at our discretion.
You’re familiar with the golden rule? He who brings the gold, makes the rule. In this case, Merck is trying, in essence, not to stifle this innovative culture without being too prescriptive or officious about what we should be working on. I think this distinguishes the deal from these contract research-type deals where the big company tells the little company what to work on. We can lead R&D up to proof of concept. And after proof of concept, Merck has the ability to exercise an option to license that program. So at that point, they would run it… We have the latitude to move into other therapeutic areas.
Xxxxxxx
F1ash - yeah maybe Merck has a bit of buyer's remorse---coulda shoulda woulda, like someday AbbVie might for PCYC perhaps? (Personally AbbVie might be a good fit for CTIX at some pt... See links below). And maybe Merck is eyeing that other Mass-based company. Who knows. But given the activity (need, incentives) in the ABX sector it's just a matter of time before CTIX, with its next gen class of compounds, announces a deal.
ABBVIE
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111325902
Ellaruth also hit on this I realized later (albeit by making difft connections)
http://m.seekingalpha.com/instablog/21116141-ellaruth/3522165-reasons-abbvie-could-be-staring-at-cellceutix
And heard of Apoptosis anyone?
http://www.abbvie.com/oncology/home/apoptosis.html
Pure unadulterated speculation of course.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM